2023 - Research.com Best Scientist Award
2023 - Research.com Medicine in United States Leader Award
2022 - Research.com Best Scientist Award
2012 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
His research on Chronic lymphocytic leukemia, Cytarabine and Chronic myelogenous leukemia is centered around Leukemia. He merges many fields, such as Chronic lymphocytic leukemia and Fludarabine, in his writings. He conducted interdisciplinary study in his works that combined Cytarabine and Chemotherapy. He conducts interdisciplinary study in the fields of Chemotherapy and Cyclophosphamide through his works. His multidisciplinary approach integrates Cyclophosphamide and Fludarabine in his work. The research on Nilotinib, Imatinib mesylate and Dasatinib is part of his Imatinib project. His Internal medicine study typically links adjacent topics like Clinical trial. He carries out multidisciplinary research, doing studies in Gastroenterology and Oncology. In his study, Hagop M. Kantarjian carries out multidisciplinary Oncology and Gastroenterology research.
As part of his inquiry into Chronic myelogenous leukemia and Chronic lymphocytic leukemia, Hagop M. Kantarjian is doing Leukemia research. Hagop M. Kantarjian carries out multidisciplinary research, doing studies in Chronic lymphocytic leukemia and Leukemia. He integrates many fields, such as Imatinib and engineering, in his works. As part of his studies on Internal medicine, Hagop M. Kantarjian often connects relevant subjects like Adverse effect. Hagop M. Kantarjian undertakes interdisciplinary study in the fields of Oncology and Gastroenterology through his works. He undertakes interdisciplinary study in the fields of Gastroenterology and Oncology through his works. His work on Dasatinib expands to the thematically related Myeloid leukemia. By researching both Gene and Biochemistry, he produces research that crosses academic boundaries. He integrates Biochemistry and Gene in his studies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng.
The New England Journal of Medicine (2001)
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
Timothy J. Ley;Christopher Miller;Li Ding;Benjamin J. Raphael.
The New England Journal of Medicine (2013)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta.
The New England Journal of Medicine (2001)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato.
The New England Journal of Medicine (2006)
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover.
The New England Journal of Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Augusta University
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
University of California, Irvine
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
University of Hertfordshire
Amazon (United States)
Chinese Academy of Sciences
Charles Sturt University
AstraZeneca (United Kingdom)
Friedrich Miescher Institute
Agricultural Research Service
University of British Columbia
University of Queensland
University of Colorado Boulder
Max Planck Institute for Chemistry
RIKEN
University of Tulsa
University of Miami
Fred Hutchinson Cancer Research Center
Leiden University Medical Center